{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:21:12Z","timestamp":1794900072442,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":316,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1K08CA248967-01"],"award-info":[{"award-number":["1K08CA248967-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32-CA244125"],"award-info":[{"award-number":["T32-CA244125"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2023.100779","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T04:59:10Z","timestamp":1700197150000},"page":"100779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications"],"prefix":"10.1016","volume":"37","author":[{"given":"Kristin","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn H.","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alysen","family":"Demzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Moreton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Wobker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-8849","authenticated-orcid":false,"given":"Marc A.","family":"Bjurlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2023.100779_bib0001","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med. Sci. (Basel)"},{"key":"10.1016\/j.ctarc.2023.100779_bib0002","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ijc.25700","article-title":"The plasmacytoid carcinoma of the bladder\u2013rare variant of aggressive urothelial carcinoma","volume":"129","author":"Keck","year":"2011","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.ctarc.2023.100779_bib0003","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.5858\/arpa.2018-0139-RS","article-title":"Plasmacytoid urothelial carcinoma: an unusual variant that warrants aggressive management and critical distinction on transurethral resections","volume":"143","author":"Sood","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ctarc.2023.100779_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s42047-020-0056-5","article-title":"Plasmocytoid urothelial carcinoma - clinical, histological, immunohistochemical and molecular aspects","volume":"3","author":"Leite","year":"2020","journal-title":"Surg. Exp. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/iju5.12463","article-title":"Pathological complete response of plasmacytoid variant bladder cancer to pembrolizumab following genomic analysis","volume":"5","author":"Goto","year":"2022","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.ctarc.2023.100779_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13000-019-0896-z","article-title":"Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile","volume":"14","author":"Simon","year":"2019","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0007","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.humpath.2009.01.001","article-title":"Plasmacytoid urothelial carcinoma of the bladder","volume":"40","author":"Lopez-Beltran","year":"2009","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0008","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.juro.2011.10.145","article-title":"Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread","volume":"187","author":"Ricardo-Gonzalez","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0009","first-page":"390","article-title":"A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin","volume":"9","author":"Sun","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11912-019-0772-8","article-title":"Clinical and genomic considerations for variant histology in bladder cancer","volume":"21","author":"Matulay","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ctarc.2023.100779_bib0011","first-page":"1","article-title":"Histologic variants of urothelial carcinoma: morphology, molecular features and clinical implications","author":"Alderson","year":"2020","journal-title":"Bl. Cancer."},{"key":"10.1016\/j.ctarc.2023.100779_bib0012","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.urology.2013.12.035","article-title":"Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes","volume":"83","author":"Kaimakliotis","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.ctarc.2023.100779_bib0013","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.urology.2016.09.053","article-title":"Outcomes following radical cystectomy for plasmacytoid urothelial carcinoma: defining the need for improved local cancer control","volume":"102","author":"Cockerill","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.ctarc.2023.100779_bib0014","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/BLC-190258","article-title":"Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes","volume":"6","author":"Diamantopoulos","year":"2020","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ctarc.2023.100779_bib0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/s41416-020-01244-2","article-title":"Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma","volume":"124","author":"Teo","year":"2021","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.ctarc.2023.100779_bib0016","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.humpath.2010.11.011","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series","volume":"42","author":"Raspollini","year":"2011","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4920236","article-title":"CK20 and CK5\/6 immunohistochemical staining of urothelial neoplasms: a perspective","volume":"2020","author":"Akhtar","year":"2020","journal-title":"Adv. Urol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8463731","article-title":"HER2 protein overexpression and gene amplification in plasmacytoid urothelial carcinoma of the urinary bladder","volume":"2016","author":"Kim","year":"2016","journal-title":"Dis. Markers."},{"key":"10.1016\/j.ctarc.2023.100779_bib0019","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/ajcp\/aqx029","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 49 cases","volume":"147","author":"Fox","year":"2017","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.humpath.2019.04.012","article-title":"Plasmacytoid\/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients","volume":"90","author":"Perrino","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.prp.2008.09.004","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder: a case report and immunohistochemical study","volume":"205","author":"Sato","year":"2009","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ctarc.2023.100779_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.07.014","article-title":"Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC","volume":"40","author":"Kossa\u00ef","year":"2022","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0023","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.923130","article-title":"Metastatic plasmacytoid bladder cancer harboring a CDH-1 mutation and producing high levels of CA 19-9. A case report and literature review","volume":"21","author":"Telfah","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.ctarc.2023.100779_bib0024","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.humpath.2014.02.023","article-title":"Differential expression of GATA-3 in urothelial carcinoma variants","volume":"45","author":"Liang","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0025","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.urolonc.2014.06.016","article-title":"Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma","volume":"32","author":"Keck","year":"2014","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0026","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.5858\/arpa.2020-0262-OA","article-title":"p-120 catenin is a useful diagnostic biomarker for distinguishing plasmacytoid and sarcomatoid variants from conventional urothelial carcinoma","volume":"145","author":"Acosta","year":"2021","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ctarc.2023.100779_bib0027","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13000-020-01043-6","article-title":"Plasmacytoid urothelial carcinoma of renal pelvis with positive zinc finger E-box-binding homeobox 1: a case report","volume":"15","author":"Takada-Owada","year":"2020","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0028","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1073\/pnas.1918167117","article-title":"The functional activity of E-cadherin controls tumor cell metastasis at multiple steps","volume":"117","author":"Na","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.ctarc.2023.100779_bib0029","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1245\/s10434-012-2709-4","article-title":"Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder","volume":"20","author":"Keck","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.humpath.2020.07.006","article-title":"Invasive plasmacytoid urothelial carcinoma: a comparative study of E-cadherin and P120 catenin","volume":"102","author":"Sangoi","year":"2020","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0031","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1349-7006.2009.01379.x","article-title":"Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma","volume":"101","author":"Shimada","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctarc.2023.100779_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2006.05.029","article-title":"Urothelial carcinoma with plasmacytoid variants producing both human chorionic gonadotropin and carbohydrate antigen 19-9","volume":"68","author":"Shimada","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.ctarc.2023.100779_bib0033","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Network","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ctarc.2023.100779_bib0034","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/his.13225","article-title":"p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant","volume":"71","author":"Hodgson","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.ctarc.2023.100779_bib0035","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1309\/AJCP1J0JPJBPSUXF","article-title":"Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants","volume":"142","author":"Li","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0036","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.humpath.2012.07.009","article-title":"Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder","volume":"44","author":"Gonzalez-Roibon","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0037","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2023.100779_bib0038","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.2022.40.6_suppl.529","article-title":"Expression of Nectin-4 and PD-L1 in bladder cancer with variant histology","volume":"40","author":"Case","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ctarc.2023.100779_bib0039","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.2147\/OTT.S135157","article-title":"PD1\/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer","volume":"11","author":"Stenehjem","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctarc.2023.100779_bib0040","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctarc.2023.100779_bib0042","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.celrep.2014.04.038","article-title":"Mutational context and diverse clonal development in early and late bladder cancer","volume":"7","author":"Nordentoft","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.ctarc.2023.100779_bib0043","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ctarc.2023.100779_bib0044","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ctarc.2023.100779_bib0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5114\/pjp.2014.45788","article-title":"High-grade urothelial carcinoma, plasmacytoid variant, of the renal pelvis with osteoclast-like giant cells and focal rhabdoid features","volume":"65","author":"Kuroda","year":"2014","journal-title":"Pol. J. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2018.10.033","article-title":"Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations","volume":"85","author":"Palsgrove","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0047","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.ctarc.2023.100779_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101820","article-title":"Hereditary diffuse gastric cancer (HDGC). An overview","volume":"46","author":"Taja-Chayeb","year":"2022","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920967238","article-title":"Hereditary diffuse gastric cancer therapeutic roadmap: current and novel approaches in a nutshell","volume":"12","author":"El Rami","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ctarc.2023.100779_bib0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/329341a0","article-title":"Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA","volume":"329","author":"Nagafuchi","year":"1987","journal-title":"Nature"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223001016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294223001016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:10:49Z","timestamp":1778893849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294223001016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":50,"alternative-id":["S2468294223001016"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100779","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2023.100779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100779"}}